

# Jason Grebely

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3273297/publications.pdf>

Version: 2024-02-01

306  
papers

18,747  
citations

16451

64  
h-index

15732

125  
g-index

313  
all docs

313  
docs citations

313  
times ranked

12419  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
2	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1192-e1207.	6.3	1,020
3	Epidemiology and natural history of HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 553-562.	17.8	833
4	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
5	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609.	7.3	431
6	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet, The</i> , 2019, 394, 1560-1579.	13.7	404
7	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. <i>Journal of Hepatology</i> , 2017, 67, 1204-1212.	3.7	390
8	Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. <i>Annals of Internal Medicine</i> , 2015, 163, 215-223.	3.9	364
9	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1208-e1220.	6.3	334
10	Elbasvirâ€“Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. <i>Annals of Internal Medicine</i> , 2016, 165, 625.	3.9	322
11	The effects of female sex, viral genotype, and <i>IL28B</i> genotype on spontaneous clearance of acute hepatitis C virus infection. <i>Hepatology</i> , 2014, 59, 109-120.	7.3	320
12	Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, S80-S89.	5.8	280
13	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. <i>JAMA Psychiatry</i> , 2021, 78, 979.	11.0	244
14	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	8.1	237
15	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	8.1	231
16	Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 408-414.	9.1	186
17	Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. <i>Drug and Alcohol Dependence</i> , 2008, 93, 141-147.	3.2	180
18	Global, regional, and countryâ€“level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	3.3	178

#	ARTICLE	IF	CITATIONS
19	Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 754-767.	8.1	174
20	Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels. <i>Journal of Infectious Diseases</i> , 2013, 207, S19-S25.	4.0	165
21	Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. <i>Journal of Viral Hepatitis</i> , 2009, 16, 352-358.	2.0	162
22	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1028-1038.	3.3	159
23	Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. <i>International Journal of Drug Policy</i> , 2017, 47, 34-46.	3.3	158
24	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 123-135.e2.	1.3	157
25	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , 2016, 65, 17-25.	3.7	157
26	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 1216-1224.	7.3	156
27	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 435-444.	8.1	145
28	Hepatitis C virus reinfection in injection drug users. <i>Hepatology</i> , 2006, 44, 1139-1145.	7.3	137
29	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	8.1	128
30	Direct-acting antiviral agents for HCV infection affecting people who inject drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 641-651.	17.8	127
31	Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there?. <i>Journal of the International AIDS Society</i> , 2017, 20, 22146.	3.0	126
32	Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 514-520.	8.1	123
33	What Is Killing People with Hepatitis C Virus Infection?. <i>Seminars in Liver Disease</i> , 2011, 31, 331-339.	3.6	122
34	Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1109-1115.	3.1	116
35	Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999–2011. <i>Journal of Viral Hepatitis</i> , 2014, 21, 198-207.	2.0	112
36	The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. <i>Addiction</i> , 2014, 109, 2053-2059.	3.3	112

#	ARTICLE	IF	CITATIONS
37	Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 270-277.	1.6	109
38	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 643-657.	3.7	103
39	Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S129-S137.	5.8	99
40	Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. <i>Clinical Infectious Diseases</i> , 2013, 57, S62-S69.	5.8	97
41	Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements. <i>Clinical Infectious Diseases</i> , 2013, 57, 1014-1020.	5.8	97
42	Can hepatitis C virus infection be eradicated in people who inject drugs?. <i>Antiviral Research</i> , 2014, 104, 62-72.	4.1	96
43	Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 52, 803-811.	5.8	95
44	Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. <i>International Journal of Drug Policy</i> , 2007, 18, 437-443.	3.3	93
45	Factors Associated with Spontaneous Clearance of Hepatitis C Virus among Illicit Drug Users. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 447-451.	1.7	92
46	Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. <i>Liver International</i> , 2014, 34, 1198-1206.	3.9	90
47	The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). <i>EBioMedicine</i> , 2016, 12, 189-195.	6.1	89
48	Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2017, 47, 77-85.	3.3	88
49	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. <i>Journal of Infectious Diseases</i> , 2018, 217, 1889-1896.	4.0	88
50	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , 2019, 39, 20-30.	3.9	88
51	Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1405-1411.	5.8	87
52	Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. <i>Hepatology</i> , 2012, 55, 1058-1069.	7.3	82
53	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC <sup>3</sup> Study. <i>Journal of Infectious Diseases</i> , 2015, 212, 1407-1419.	4.0	82
54	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1479-1481.	5.8	81

#	ARTICLE	IF	CITATIONS
55	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	8.1	80
56	Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 218-230.	17.8	79
57	Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, S22-S26.	3.3	78
58	The removal of DAA restrictions in Europe — One step closer to eliminating HCV as a major public health threat. <i>Journal of Hepatology</i> , 2018, 69, 1188-1196.	3.7	78
59	Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. <i>Journal of Hepatology</i> , 2019, 71, 281-288.	3.7	76
60	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E605-E614.	2.4	74
61	COVID-19 and the health of people who use drugs: What is and what could be?. <i>International Journal of Drug Policy</i> , 2020, 83, 102958.	3.3	74
62	Reinfection with hepatitis C virus following sustained virological response in injection drug users. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1281-1284.	2.8	69
63	Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1519-1525.	2.8	68
64	Management of HCV and HIV infections among people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 501-507.	3.8	68
65	Hepatitis C Virus Phylogenetic Clustering Is Associated with the Social-Injecting Network in a Cohort of People Who Inject Drugs. <i>PLoS ONE</i> , 2012, 7, e47335.	2.5	68
66	<scp>HCV</scp> reinfection incidence among individuals treated for recent infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 359-370.	2.0	68
67	Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 640-648.	2.0	68
68	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 73, 172-184.	3.3	67
69	Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. <i>Journal of Hepatology</i> , 2019, 70, 33-39.	3.7	66
70	Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. <i>International Journal of Drug Policy</i> , 2015, 26, 992-998.	3.3	65
71	The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design. <i>Journal of Infectious Diseases</i> , 2012, 205, 1342-1350.	4.0	64
72	Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. <i>Drug and Alcohol Review</i> , 2012, 31, 918-924.	2.1	63

#	ARTICLE	IF	CITATIONS
73	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. <i>Addiction</i> , 2016, 111, 311-319.	3.3	63
74	Management of acute HCV infection in the era of direct-acting antiviral therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 412-424.	17.8	62
75	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. <i>Hepatology</i> , 2013, 57, 2124-2134.	7.3	61
76	Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 229-236.	2.8	61
77	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 733-741.	2.0	61
78	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. <i>Clinical Infectious Diseases</i> , 2017, 64, 860-869.	5.8	61
79	Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. <i>Hepatology</i> , 2014, 60, 1571-1580.	7.3	59
80	Reply. <i>Hepatology</i> , 2007, 45, 1331-1331.	7.3	58
81	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. <i>Journal of Hepatology</i> , 2018, 68, 393-401.	3.7	58
82	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	3.3	58
83	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 83-92.	2.0	58
84	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2018, 61, 23-30.	3.3	57
85	Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. <i>Journal of Viral Hepatitis</i> , 2011, 18, e104-16.	2.0	56
86	The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. <i>Drug and Alcohol Dependence</i> , 2007, 89, 306-309.	3.2	54
87	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	3.3	54
88	Treatment of acute HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 265-274.	17.8	53
89	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. <i>Journal of Hepatology</i> , 2011, 55, 76-85.	3.7	53
90	High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e80216.	2.5	53

#	ARTICLE	IF	CITATIONS
91	Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. <i>Journal of Viral Hepatitis</i> , 2014, 21, 560-567.	2.0	53
92	Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. <i>International Journal of Drug Policy</i> , 2017, 47, 26-33.	3.3	53
93	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , 2020, 71, e115-e124.	5.8	53
94	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. <i>Clinical Infectious Diseases</i> , 2019, 69, 2218-2227.	5.8	52
95	Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveLife Study. <i>International Journal of Drug Policy</i> , 2015, 26, 984-991.	3.3	50
96	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE II study. <i>Hepatology</i> , 2016, 64, 1911-1921.	7.3	50
97	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 426-445.	8.1	50
98	Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. <i>Journal of Viral Hepatitis</i> , 2011, 18, 32-41.	2.0	48
99	Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. <i>International Journal of Epidemiology</i> , 2013, 42, 1649-1659.	1.9	48
100	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 533-546.	8.1	48
101	The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0131437.	2.5	48
102	Case definitions for acute hepatitis C virus infection: A systematic review. <i>Journal of Hepatology</i> , 2012, 57, 1349-1360.	3.7	46
103	Excluding people who use drugs or alcohol from access to hepatitis C treatments “Is this fair, given the available data?”. <i>Journal of Hepatology</i> , 2015, 63, 779-782.	3.7	46
104	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. <i>Current HIV/AIDS Reports</i> , 2017, 14, 110-121.	3.1	46
105	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. <i>International Journal of Drug Policy</i> , 2018, 54, 18-25.	3.3	46
106	Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The SCOPE Study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1094-1104.	2.0	46
107	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
108	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. <i>International Journal of Drug Policy</i> , 2015, 26, 976-983.	3.3	44

#	ARTICLE	IF	CITATIONS
109	Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1526-1532.	2.0	44
110	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107793.	3.2	44
111	Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. <i>International Journal of Drug Policy</i> , 2014, 25, 179-182.	3.3	43
112	Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. <i>International Journal of Drug Policy</i> , 2015, 26, 999-1006.	3.3	43
113	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e69-e78.	5.8	43
114	Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2011, 116, 52-56.	3.2	42
115	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. <i>International Journal of Drug Policy</i> , 2015, 26, 950-957.	3.3	42
116	Global elimination of hepatitis C virus by 2030: why not?. <i>Nature Medicine</i> , 2020, 26, 157-160.	30.7	42
117	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. <i>PLoS ONE</i> , 2015, 10, e0122232.	2.5	41
118	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. <i>International Journal of Drug Policy</i> , 2019, 72, 1-10.	3.3	40
119	Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists: The practitioner experience. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107705.	3.2	40
120	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 281-293.	2.0	39
121	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e107-e118.	5.8	39
122	Effect of pegylated interferon- $\alpha$ 2a treatment on mental health during recent hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 957-965.	2.8	38
123	Estimating the number of people who inject drugs in Australia. <i>BMC Public Health</i> , 2017, 17, 757.	2.9	38
124	Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?. <i>PLoS ONE</i> , 2015, 10, e0143836.	2.5	37
125	Prevention of Hepatitis C Virus in Injecting Drug Users: A Narrow Window of Opportunity. <i>Journal of Infectious Diseases</i> , 2011, 203, 571-574.	4.0	36
126	Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012. <i>PLoS ONE</i> , 2014, 9, e97726.	2.5	36



#	ARTICLE	IF	CITATIONS
127	Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment. <i>Journal of Hepatology</i> , 2015, 62, 269-277.	3.7	36
128	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). <i>Journal of Hepatology</i> , 2016, 65, 1086-1093.	3.7	36
129	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy001.	0.9	36
130	Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review. <i>International Journal of Drug Policy</i> , 2012, 23, 176-184.	3.3	35
131	Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. <i>Drug and Alcohol Dependence</i> , 2010, 107, 244-249.	3.2	33
132	Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 893-898.	3.3	33
133	Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. <i>Drug and Alcohol Dependence</i> , 2019, 194, 487-494.	3.2	33
134	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. <i>Journal of Clinical Virology</i> , 2017, 92, 32-38.	3.1	32
135	Directly Observed Pegylated Interferon Plus Self-Administered Ribavirin for the Treatment of Hepatitis C Virus Infection in People Actively Using Drugs: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, S90-S96.	5.8	30
136	Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. <i>Drug and Alcohol Dependence</i> , 2015, 152, 272-276.	3.2	29
137	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. <i>Journal of Hepatology</i> , 2016, 65, 879-887.	3.7	29
138	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators?. <i>Journal of Infectious Diseases</i> , 2019, 220, 78-90.	4.0	29
139	Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2019, 66, 73-79.	3.3	29
140	Current Approaches to HCV Infection in Current and Former Injection Drug Users. <i>Journal of Addictive Diseases</i> , 2008, 27, 25-35.	1.3	28
141	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 230-238.	3.3	28
142	Virological responses during treatment for recent hepatitis C virus. <i>Aids</i> , 2012, 26, 1653-1661.	2.2	27
143	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 371-393.	5.1	27
144	An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. <i>International Journal of Drug Policy</i> , 2019, 72, 99-105.	3.3	27

#	ARTICLE	IF	CITATIONS
145	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. <i>Journal of Hepatology</i> , 2021, 74, 293-302.	3.7	27
146	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	3.7	27
147	Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. <i>Drug and Alcohol Dependence</i> , 2013, 133, 529-534.	3.2	26
148	Dynamics of HCV RNA levels during acute hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2014, 86, 1722-1729.	5.0	26
149	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	5.8	26
150	Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1340-1354.	2.0	26
151	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	4.3	26
152	Sequencing of the Hepatitis C Virus: A Systematic Review. <i>PLoS ONE</i> , 2013, 8, e67073.	2.5	25
153	Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1180-1188.	2.0	25
154	Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 969-979.	2.0	25
155	Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study. <i>Journal of Viral Hepatitis</i> , 2015, 22, 914-925.	2.0	24
156	Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. <i>Hepatology</i> , 2020, 72, 7-18.	7.3	24
157	Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. <i>Journal of Infectious Diseases</i> , 2022, 226, 1005-1021.	4.0	24
158	A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events. <i>Infection, Genetics and Evolution</i> , 2015, 33, 101-109.	2.3	23
159	A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. <i>Journal of Viral Hepatitis</i> , 2017, 24, 404-411.	2.0	23
160	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	3.3	22
161	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	2.9	22
162	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. <i>Liver International</i> , 2020, 40, 778-786.	3.9	22

#	ARTICLE	IF	CITATIONS
163	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
164	Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 199-208.	1.0	21
165	A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 745-752.	3.7	21
166	SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. <i>Journal of Hepatology</i> , 2017, 66, S513-S514.	3.7	21
167	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. <i>Clinical Infectious Diseases</i> , 2018, 66, 20-28.	5.8	21
168	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 76, 102619.	3.3	21
169	Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. <i>International Journal of Drug Policy</i> , 2019, 66, 87-93.	3.3	20
170	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. <i>International Journal of Drug Policy</i> , 2020, 77, 102656.	3.3	20
171	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. <i>Lancet Psychiatry</i> , 2021, 8, 301-309.	7.4	20
172	HCV reinfection studies and the door to vaccine development. <i>Journal of Hepatology</i> , 2009, 51, 628-631.	3.7	19
173	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 473-481.	2.0	19
174	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2369-2376.	5.8	19
175	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2020, 8, e76-e91.	6.3	19
176	Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107744.	3.2	19
177	Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: A population-level tool for incidence estimation. <i>Hepatology</i> , 2015, 61, 1842-1850.	7.3	18
178	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. <i>International Journal of Drug Policy</i> , 2015, 26, 1094-1102.	3.3	18
179	Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. <i>Journal of Hepatology</i> , 2016, 64, 1247-1255.	3.7	18
180	Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. <i>International Journal of Drug Policy</i> , 2019, 72, 106-113.	3.3	18

#	ARTICLE	IF	CITATIONS
181	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 621-627.	2.8	17
182	Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: The C-SCOPE study. <i>International Journal of Drug Policy</i> , 2019, 63, 29-38.	3.3	17
183	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 84, 102866.	3.3	17
184	Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. <i>JAMA Network Open</i> , 2020, 3, e204192.	5.9	17
185	Delivery of treatment for hepatitis C virus infection in the primary care setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1003-1009.	1.6	16
186	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. <i>Journal of Infectious Diseases</i> , 2016, 214, 1383-1389.	4.0	16
187	Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots. <i>Journal of Clinical Virology</i> , 2019, 112, 40-44.	3.1	16
188	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 70, 87-93.	3.3	16
189	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 2043-2049.	4.0	16
190	Treatment of HCV in persons who inject drugs: Treatment as prevention. <i>Clinical Liver Disease</i> , 2017, 9, 77-80.	2.1	15
191	Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. <i>Journal of Hepatology</i> , 2017, 66, S95-S96.	3.7	15
192	Novel Hepatitis C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. <i>Journal of Infectious Diseases</i> , 2020, 222, S758-S772.	4.0	15
193	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. <i>PLoS ONE</i> , 2016, 11, e0150655.	2.5	15
194	A Systematic Approach to the Treatment of HIV and Hepatitis C Virus Infection in the Inner City: A Canadian Perspective. <i>Clinical Infectious Diseases</i> , 2005, 41, S73-S78.	5.8	14
195	Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn. <i>Hepatology</i> , 2014, 60, 2127-2128.	7.3	14
196	Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20141197.	3.4	14
197	Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing. <i>Infection, Genetics and Evolution</i> , 2016, 43, 329-337.	2.3	14
198	Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, 1101-1103.	3.7	14

#	ARTICLE	IF	CITATIONS
199	Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC <sup>3</sup> Study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 43-52.	2.0	14
200	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. <i>Infection, Genetics and Evolution</i> , 2019, 71, 36-41.	2.3	14
201	“That was quick, simple, and easy”: Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. <i>International Journal of Drug Policy</i> , 2022, 99, 103456.	3.3	14
202	A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. <i>Seminars in Liver Disease</i> , 2022, 42, 159-172.	3.6	14
203	Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. <i>International Journal of Drug Policy</i> , 2022, 105, 103706.	3.3	14
204	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC <sup>3</sup> study. <i>Journal of Viral Hepatitis</i> , 2015, 22, 708-717.	2.0	13
205	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2016, 37, 252-258.	2.3	13
206	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 177-186.	3.3	13
207	Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. <i>PLoS ONE</i> , 2021, 16, e0257369.	2.5	13
208	Lower life expectancy among people with an HCV notification: a population-based linkage study. <i>Journal of Viral Hepatitis</i> , 2014, 21, e10-8.	2.0	12
209	Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. <i>Scientific Reports</i> , 2017, 7, 41719.	3.3	12
210	Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1423-1430.	2.0	12
211	Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. <i>International Journal of Drug Policy</i> , 2020, 77, 102693.	3.3	12
212	Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2010, 17, 896-896.	2.0	11
213	Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. <i>CMAJ Open</i> , 2013, 1, E68-E76.	2.4	11
214	Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: A 15-year observational cohort study. <i>Drug and Alcohol Dependence</i> , 2015, 148, 213-216.	3.2	11
215	Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 37-42.	2.0	11
216	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. <i>Addiction</i> , 2018, 113, 1768-1774.	3.3	11

#	ARTICLE	IF	CITATIONS
217	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1388-1403.	2.0	11
218	Methadone Dosing Strategies in HIV-Infected Injection Drug Users Enrolled in a Directly Observed Therapy Program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 324-327.	2.1	11
219	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1809-1819.	5.8	11
220	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. <i>Journal of Viral Hepatitis</i> , 2015, 22, 1020-1032.	2.0	10
221	The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. <i>Drug and Alcohol Dependence</i> , 2016, 169, 156-162.	3.2	10
222	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , 2016, 13, 32.	3.4	10
223	“I didn’t want to let it go too far.” The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. <i>International Journal of Drug Policy</i> , 2017, 47, 153-160.	3.3	10
224	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	4.9	10
225	Moving the Agenda Forward: The Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S29-S31.	5.8	9
226	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. <i>PLoS ONE</i> , 2013, 8, e80003.	2.5	9
227	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. <i>Journal of Addiction Medicine</i> , 2017, 11, 10-18.	2.6	9
228	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
229	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 1664-1676.	3.3	9
230	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2037-2044.	5.8	9
231	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons. <i>Hepatology</i> , 2021, 74, 2366-2379.	7.3	9
232	Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109050.	3.2	9
233	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. <i>Journal of Clinical Virology</i> , 2014, 61, 430-434.	3.1	8
234	HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2016, 11, e0154433.	2.5	8

#	ARTICLE	IF	CITATIONS
235	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. <i>Liver International</i> , 2016, 36, 1774-1782.	3.9	8
236	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. <i>Infection, Genetics and Evolution</i> , 2017, 49, 88-96.	2.3	8
237	Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030. <i>Journal of Hepatology</i> , 2017, 67, 419-420.	3.7	8
238	The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments. <i>Journal of Hepatology</i> , 2017, 66, S291-S292.	3.7	8
239	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). <i>Hepatology Communications</i> , 2017, 1, 736-747.	4.3	8
240	Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. <i>Medical Journal of Australia</i> , 2021, 215, 332-333.	1.7	8
241	Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. <i>Sexual Health</i> , 2020, 17, 223.	0.9	8
242	Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia. <i>Viruses</i> , 2022, 14, 1496.	3.3	8
243	Primary drug resistance in antiretroviral-naïve injection drug users. <i>International Journal of Infectious Diseases</i> , 2009, 13, 577-583.	3.3	7
244	Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. <i>Clinical Infectious Diseases</i> , 2020, 70, 123-131.	5.8	7
245	Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingertick Capillary Dried Blood Spot and Venepuncture-Collected Samples. <i>Journal of Infectious Diseases</i> , 2021, 223, 818-826.	4.0	7
246	The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?. <i>Canadian Liver Journal</i> , 2018, 1, 4-13.	0.9	7
247	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. <i>International Journal of Drug Policy</i> , 2021, 96, 103469.	3.3	7
248	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. <i>Viruses</i> , 2022, 14, 1555.	3.3	7
249	The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure. <i>Journal of Hepatology</i> , 2008, 49, 305-307.	3.7	6
250	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 425-434.	1.0	6
251	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. <i>BMC Infectious Diseases</i> , 2017, 17, 420.	2.9	6
252	O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study. <i>Journal of Virus Eradication</i> , 2017, 3, 8.	0.5	6

#	ARTICLE	IF	CITATIONS
253	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , 2018, 90, 120-130.	5.0	6
254	Hepatitis C: A Canadian perspective. <i>Canadian Liver Journal</i> , 2018, 1, 1-3.	0.9	6
255	A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. <i>Journal of the International AIDS Society</i> , 2019, 22, e25222.	3.0	6
256	Genomic variability of within-host hepatitis C variants in acute infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 476-484.	2.0	6
257	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. <i>Infection, Genetics and Evolution</i> , 2019, 69, 76-84.	2.3	6
258	SHARED: An International Collaboration to Unravel Hepatitis C Resistance. <i>Viruses</i> , 2021, 13, 1580.	3.3	6
259	Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment. <i>Drug and Alcohol Dependence</i> , 2022, 235, 109438.	3.2	6
260	Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109543.	3.2	6
261	60 DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN. <i>Journal of Hepatology</i> , 2010, 52, S28.	3.7	5
262	Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?. <i>Hepatology</i> , 2014, 59, 1650-1651.	7.3	5
263	Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all. <i>Journal of Viral Hepatitis</i> , 2016, 23, 664-666.	2.0	5
264	Hepatitis C Virus Treatment and Persons Who Inject Drugs. <i>Annals of Internal Medicine</i> , 2016, 164, 203.	3.9	5
265	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 465-465.	1.0	5
266	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2016, 16, 241.	2.9	5
267	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy248.	0.9	5
268	SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression. <i>Journal of Hepatology</i> , 2019, 70, e733.	3.7	5
269	Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montreal, Canada. <i>Addiction</i> , 2019, 114, 1495-1503.	3.3	5
270	Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. <i>International Journal of Drug Policy</i> , 2020, 86, 102964.	3.3	5



#	ARTICLE	IF	CITATIONS
271	Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study. <i>International Journal of Drug Policy</i> , 2021, 96, 103421.	3.3	5
272	Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. <i>International Journal of Drug Policy</i> , 2021, 96, 103439.	3.3	5
273	“Not just one box that you tick off” – Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. <i>International Journal of Drug Policy</i> , 2022, 102, 103610.	3.3	5
274	On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvir with or without Ribavirin in the Phase 3 ION-1 Study. <i>Journal of Hepatology</i> , 2016, 64, S776-S777.	3.7	4
275	Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach. <i>Journal of Viral Hepatitis</i> , 2018, 25, 28-36.	2.0	4
276	6th Canadian Symposium on Hepatitis C Virus: Delivering a cure for hepatitis C infection – What are the remaining gaps?. <i>Canadian Liver Journal</i> , 2018, 1, 94-105.	0.9	4
277	Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake. <i>Journal of Hepatology</i> , 2018, 68, S153.	3.7	4
278	THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. <i>Journal of Hepatology</i> , 2019, 70, e231.	3.7	4
279	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO): An open-label, single-arm, phase 4, multicentre trial. <i>Health Science Reports</i> , 2020, 3, e151.	1.5	4
280	Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. <i>Drug and Alcohol Review</i> , 2021, 40, 1349-1353.	2.1	4
281	Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. <i>International Journal of Drug Policy</i> , 2021, 96, 103418.	3.3	4
282	Interferon Î» 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 583-589.	2.8	3
283	Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study. <i>Journal of Hepatology</i> , 2017, 66, S274.	3.7	3
284	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107899.	3.2	3
285	Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel. <i>International Journal of Drug Policy</i> , 2021, 98, 103379.	3.3	3
286	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	3.3	3
287	Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy. <i>The Open Virology Journal</i> , 2007, 1, 8-13.	1.8	3
288	Direct-acting antivirals for acute HCV: how short can we go?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 316-318.	8.1	2

#	ARTICLE	IF	CITATIONS
289	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	3.3	2
290	Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study. <i>Journal of Hepatology</i> , 2018, 68, S187-S188.	3.7	2
291	PS-070-Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study. <i>Journal of Hepatology</i> , 2019, 70, e42.	3.7	2
292	Cure and Control: What Will It Take to Eliminate HCV?. <i>Topics in Medicinal Chemistry</i> , 2019, , 447-490.	0.8	2
293	Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. <i>International Journal of Drug Policy</i> , 2021, 96, 103419.	3.3	2
294	“You need a designated officer” Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting. <i>International Journal of Drug Policy</i> , 2022, 106, 103746.	3.3	2
295	Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw024.	0.9	1
296	Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study. <i>Journal of Hepatology</i> , 2020, 73, S807-S808.	3.7	1
297	Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C. <i>Liver International</i> , 2020, 40, 2353-2355.	3.9	1
298	The 8th Canadian Symposium on Hepatitis C virus: “Improving diagnosis and linkage to care”. <i>Canadian Liver Journal</i> , 2020, 3, 3-14.	0.9	1
299	Systematic approach to the treatment of HCV infection in injection drug users: where are we now?. <i>Future Virology</i> , 2009, 4, 411-413.	1.8	0
300	P232 MOLECULAR PHYLOGENETICS OF HEPATITIS C VIRUS (HCV) AS A TOOL TO UNDERSTAND THE HCV EPIDEMIC IN BRITISH COLUMBIA (BC), CANADA. <i>Journal of Hepatology</i> , 2014, 60, S143.	3.7	0
301	Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection. <i>International Journal of Drug Policy</i> , 2015, , 101669.	3.3	0
302	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. <i>International Journal of Drug Policy</i> , 2015, , 101671.	3.3	0
303	P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study. <i>Journal of Hepatology</i> , 2015, 62, S657.	3.7	0
304	Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1039-1040.	3.3	0
305	One-year injecting frequency trajectories as predictors of hepatitis C acquisition: findings from an observational cohort study of people who inject drugs in Montreal, Canada. <i>Journal of Hepatology</i> , 2018, 68, S189.	3.7	0
306	Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study. <i>Journal of Hepatology</i> , 2018, 68, S179-S180.	3.7	0